BRAF and neoplasm: BRAF inhibitors such as vemurafenib or dabrafenib efficiently block signaling downstream of the mutated BRAFV600 protein, which initially results in profound growth inhibition of the melanoma cells [1,2] and high frequency of tumor regression in the clinic [3,4].